Roche (OTCMKTS:RHHBY) versus PolyPid (NASDAQ:PYPD) Financial Survey

Roche (OTCMKTS:RHHBY) and PolyPid (NASDAQ:PYPD) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Institutional & Insider Ownership

26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Roche and PolyPid, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roche	0	6	5	0	2.45
PolyPid	1	0	3	0	2.50

Roche currently has a consensus target price of $60.00, suggesting a potential upside of 5.47%. PolyPid has a consensus target price of $11.33, suggesting a potential upside of 121.79%. Given PolyPid’s stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than Roche.

Profitability

This table compares Roche and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Roche	N/A	N/A	N/A
PolyPid	N/A	-311.08%	-150.83%

Volatility & Risk

Roche has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Earnings and Valuation

This table compares Roche and PolyPid”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roche	$76.45 billion	4.74	$15.55 billion	N/A	N/A
PolyPid	N/A	N/A	-$34.17 million	($1.48)	-3.45

Roche has higher revenue and earnings than PolyPid.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.